Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. Rosenstock J, et al. Among authors: davies m. Diabetologia. 2008 Mar;51(3):408-16. doi: 10.1007/s00125-007-0911-x. Epub 2008 Jan 16. Diabetologia. 2008. PMID: 18204830 Free PMC article. Clinical Trial.
Diabetes: glycaemic control in type 2.
Srinivasan B, Taub N, Khunti K, Davies M. Srinivasan B, et al. Among authors: davies m. BMJ Clin Evid. 2008 Mar 4;2008:0609. BMJ Clin Evid. 2008. PMID: 19450326 Free PMC article. Review.
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators. Rosenstock J, et al. Among authors: davies m. Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15. Diabetes Care. 2016. PMID: 27527848 Clinical Trial.
A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.
Raccah D, Chou E, Colagiuri S, Gaàl Z, Lavalle F, Mkrtumyan A, Nikonova E, Tentolouris N, Vidal J, Davies M. Raccah D, et al. Among authors: davies m. Diabetes Metab Res Rev. 2017 Mar;33(3):e2858. doi: 10.1002/dmrr.2858. Epub 2016 Oct 13. Diabetes Metab Res Rev. 2017. PMID: 27606888 Free PMC article.
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.
Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators. Rosenstock J, et al. Among authors: davies m. Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06c. Epub 2017 Apr 18. Diabetes Care. 2017. PMID: 28420696 Free PMC article. No abstract available.
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J. Davies MJ, et al. Diabetes Obes Metab. 2017 Dec;19(12):1798-1804. doi: 10.1111/dom.12980. Epub 2017 Jul 7. Diabetes Obes Metab. 2017. PMID: 28432746 Free PMC article. Clinical Trial.
6,903 results